Gardasil-9

ApprovedBiologic

BBeijing Health Guard Biotechnology, Inc

Gardasil-9 is one of 94 biologic programs targeting Cervical Intraepithelial Neoplasia. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cervical Intraepithelial NeoplasiaActive, not recruiting

Cervical CancerActive, not recruiting

PapillomaActive, not recruiting

Cervical Intraepithelial NeoplasiaPhase 3

Active, not recruiting

Cervical CancerApproved

Active, not recruiting

PapillomaPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

380 competitors in Cervical Cancer

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 3

13 2

Gemzar

Johnson & Johnson

Phase 3

8 3

Trodelvy

Gilead

Phase 3

5 4

Camptosar

Pfizer

Phase 3

4 5

Trexall

Alnylam Pharmaceuticals

Phase 3

1 6

Epogen

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Phase 3

1 7

Gemzar

GGynecologic Oncology Group

Phase 3

2 8

Blenoxane

SSequus Pharmaceuticals

Phase 3

1 9

Platinum Based Chemotherapy

Roche

Phase 3

1 10

Gardasil-9

BBeijing Health Guard Biotechnology, Inc

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Active, not recruiting

Papilloma

NCT03519464

Q1 2028

Phase 3Active, not recruiting

Immunogenicity

NCT05662020

Q2 2028

Phase 3Not yet recruiting

Cervical Intraepithelial Neoplasia

NCT03848039

Q3 2028

Post-ApprovalRecruiting

HPV Vaccine

NCT06799494

Clinical

Trials by Indication[1]

Papilloma4 trials

Immunogenicity of the 9-Valent Human Papillomavirus Recombinant Vaccine in People With Idiopathic CD4 T Cell Lymphocytopenia

Active, not recruiting·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT03519464·54 enrolled

A Study to Evaluate the Immunogenicity and Safety of Nonavalent Human Papillomavirus (HPV) Vaccine

Unknown status·BBeijing Health Guard Biotechnology, Inc·Phase 3·NCT06207175·1,260 enrolled

A Study on the Immune Response and Safety of an Adjuvanted Human Papillomavirus Vaccine When Given to Healthy Women 16 to 26 Years of Age

Completed· GSK logo

GSK·Phase 1/2·NCT05496231·1,080 enrolled

Show 1 more trial

Occupational Exposure to Human Papilloma Virus (HPV) and Prophylactic Vaccination

Unknown status·—·Phase 4·NCT03350698·100 enrolled

HPV Vaccination2 trials

HPV Vaccination in HIV Infected and HIV Uninfected Adolescents in Eswatini

Completed·—·Phase 4·NCT04982614·1,403 enrolled

Developing and Evaluating a Novel Approach to Improve HPV Vaccination Coverage Among High-risk, Under-immunized Adults Via the Emergency Department

Terminated·UUniversity of Alabama at Birmingham··NCT06229353·34 enrolled

Immunogenicity2 trials

Phase III Study Comparing the Immunogenicity of 9-valent HPV Recombinant Vaccine and Gardasil-9

Unknown status·SShanghai Zerun Biotechnology Co.,Ltd·Phase 3·NCT05580341·1,200 enrolled

A Study to Evaluate the Immunogenicity and Safety of HPV Vaccine in Healthy Female Participants Aged 9-26 Years in China

Active, not recruiting·BBeijing Health Guard Biotechnology, Inc·Phase 3·NCT05662020·2,750 enrolled

Antibody Response1 trial

Assessing Durable Antibody Response to HPV Vaccination

Active, not recruiting·EEmory University·Phase 4·NCT05031078·17 enrolled

Cervical Cancer1 trial

Faster Elimination of HPV Infection and Cervical Cancer Using Concomitant HPV Vaccination and HPV Screening: A Demonstration Project in Rwanda

Not yet recruiting·—·Phase 4·NCT06536855·100,000 enrolled

3 more indications

HPV Infection1 trial

Efficacy of Lentinula Edodes-Derived Supplement (AHCC®) in Promoting Negativity of Persistent HPV Infection

Completed·LLiaquat University of Medical & Health Sciences··NCT06752083·289 enrolled

Cervical Intraepithelial Neoplasia1 trial

Impact on Disease Relapse of HPV Vaccination in Women Treated With LEEP for Cervical Intraepithelial Neoplasia. HOPE9

Not yet recruiting·AAlessandro Ghelardi·Phase 3·NCT03848039·1,220 enrolled

HPV Vaccine1 trial

HPV Vaccine Reduced Dose

Recruiting·EEmory University·Phase 4·NCT06799494·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 13 trial records for Gardasil-9. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Gardasil-9 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Gardasil-9. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Beijing Health Guard Biotechnology, Inc company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Approved[1]
Company: BBeijing Health Guard Biotechnology, Inc

Gardasil-9

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2028

Q2 2028

Q3 2028

Trials by Indication[1]

Papilloma4 trials

HPV Vaccination2 trials

Immunogenicity2 trials

Antibody Response1 trial

Cervical Cancer1 trial

HPV Infection1 trial

Cervical Intraepithelial Neoplasia1 trial

HPV Vaccine1 trial

References

Drug Info

Quick Facts

Related News